| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c22f78ac486adee4534dc1c3a59f5de0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7064
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-067
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-067
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7064
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| filingDate |
2014-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ee81137f6a8cfb95209aacd64a3cf38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5e4edf91c0cf6afd06877a22f99915e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98c9ebef0a7fd27039b70eb7f021dfe6 |
| publicationDate |
2016-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20160079886-A |
| titleOfInvention |
Mutual prodrug comprising short chain fatty acids and zebularine or 1'-cyano-cytarabine for cancer treatment |
| abstract |
The present invention relates to a mutant prodrug comprising an anticancer nucleoside and a short chain fatty acid; A method for producing the reciprocal prodrug; A method of treatment comprising administering said reciprocal prodrug; And a pharmaceutical composition comprising the mutual prodrug. In addition, the mutant prodrug of the present invention can be used as a therapeutic agent for the treatment of cancer diseases and symptoms. |
| priorityDate |
2013-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |